Literature DB >> 14753849

Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines.

Nobuyuki Asada1, Yoshiharu Tanaka, Yasutaka Hayashido, Shigeaki Toratani, Mikio Kan, Mikiya Kitamoto, Toshio Nakanishi, Goro Kajiyama, Kazuaki Chayama, Tetsuji Okamoto.   

Abstract

The fibroblast growth factor (FGF) function has been considered to contribute to various human tumors and malignant growth of neoplasm. Hepatocellular carcinoma (HCC) is a typical hypervascular tumor, and it is suggested that FGF may be involved in hepatocarcinogenesis. Therefore, the relationship between the progression of HCC and expression of FGFs and FGF receptors (FGFRs) was evaluated in this study. We investigated the expression of messenger ribonucleic acids (mRNAs) of FGFs and FGFRs by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis in eight human hepatoma-derived cell lines (Hep3B, HLE, HLF, HUH6, HUH7, KIM1, Li7, and PLC/PRF/5), one hepatoblastoma-derived cell line (HepG2), and human primary hepatocytes. In addition, effects of FGF-1, FGF-2, and FGF-7 on the growth of hepatoma-derived cell lines were studied in serum-free defined culture conditions. An RT-PCR analysis revealed that all cell lines except PLC/PRF/5 expressed all FGFR mRNAs: FGF-R1 (IIIc), -R2 (IIIb), -R2 (IIIc), -R3 (IIIb), -R3 (IIIc), and -R4 mRNAs. In contrast, human primary hepatocytes expressed FGF-R1 (IIIc), -R3 (IIIc), and -R4 mRNAs but not mRNAs of FGF-R2 (IIIb), -R2 (IIIc), and -R3 (IIIb). All cell lines except HUH6 and HUH7 expressed FGF-1 and FGF-2 mRNAs. Addition of exogenous FGF-1 or FGF-2 (or both) to culture stimulated cell proliferation in several cell lines, but FGF-7 exhibited no growth stimulation in all cells. Hepatoma cells may possess a proliferation mechanism regulated by an autocrine mechanism, a paracrine mechanism, or both, which are mediated by FGF-1/FGFR or FGF-2/FGFR (or both). In addition, a gain of FGF-R2 (IIIb), -R2 (IIIc), and -R3 (IIIb) may be associated with malignant transformation of liver tumor and may eventually serve as useful diagnostic and prognostic indicators.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14753849     DOI: 10.1290/1543-706X(2003)039<0321:EOFGFR>2.0.CO;2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  52 in total

Review 1.  FGFs, heparan sulfate and FGFRs: complex interactions essential for development.

Authors:  D M Ornitz
Journal:  Bioessays       Date:  2000-02       Impact factor: 4.345

2.  Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase.

Authors:  M Kan; X Wu; F Wang; W L McKeehan
Journal:  J Biol Chem       Date:  1999-05-28       Impact factor: 5.157

3.  Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture.

Authors:  N Kamata; K Chida; K Rikimaru; M Horikoshi; S Enomoto; T Kuroki
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

4.  Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells.

Authors:  A Tanaka; K Miyamoto; N Minamino; M Takeda; B Sato; H Matsuo; K Matsumoto
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

5.  Keratinocyte growth factor and fibroblast growth factor action on DNA synthesis in rat and human hepatocytes: modulation by heparin.

Authors:  A J Strain; G McGuinness; J S Rubin; S A Aaronson
Journal:  Exp Cell Res       Date:  1994-02       Impact factor: 3.905

6.  Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene.

Authors:  T Miki; D P Bottaro; T P Fleming; C L Smith; W H Burgess; A M Chan; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

7.  Transformation of mouse BALB/c 3T3 cells with human basic fibroblast growth factor cDNA.

Authors:  R Sasada; T Kurokawa; M Iwane; K Igarashi
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

8.  Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1.

Authors:  A T Chellaiah; D G McEwen; S Werner; J Xu; D M Ornitz
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

9.  Immunocytochemical localization of fibroblast growth factor-1 (FGF-1) and FGF-2 in oral squamous cell carcinoma (SCC).

Authors:  Y Myoken; Y Myoken; T Okamoto; J D Sato; K Takada
Journal:  J Oral Pathol Med       Date:  1994-11       Impact factor: 4.253

10.  FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern.

Authors:  J Partanen; T P Mäkelä; E Eerola; J Korhonen; H Hirvonen; L Claesson-Welsh; K Alitalo
Journal:  EMBO J       Date:  1991-06       Impact factor: 11.598

View more
  7 in total

1.  An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways.

Authors:  Yoshihiro Adachi; Tamotsu Takeuchi; Hiroshi Sonobe; Yuji Ohtsuki
Journal:  Virchows Arch       Date:  2005-11-05       Impact factor: 4.064

2.  A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.

Authors:  Lihong Wang; Hangil Park; Sophea Chhim; Yi Ding; Wei Jiang; Cary Queen; K Jin Kim
Journal:  Mol Cancer Ther       Date:  2012-02-16       Impact factor: 6.261

3.  Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo.

Authors:  Shigeru Sasaki; Tadao Ishida; Minoru Toyota; Akinobu Ota; Hiromu Suzuki; Akinori Takaoka; Hiroshi Yasui; Hiroyuki Yamamoto; Hideyasu Takagi; Masahiro Maeda; Tsutomu Seito; Masayuki Tsujisaki; Yasuhisa Shinomura; Kohzoh Imai
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

4.  Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.

Authors:  Thi Bich Uyen Le; Thanh Chung Vu; Rebecca Zhi Wen Ho; Aldo Prawira; Lingzhi Wang; Boon Cher Goh; Hung Huynh
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

Review 5.  Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.

Authors:  Haijun Wang; Jie Yang; Ke Zhang; Jia Liu; Yushan Li; Wei Su; Na Song
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 6.  Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies.

Authors:  Rishi Raj Rikhi; Kimberlee K Spady; Ruth I Hoffman; Michael S Bateman; Max Bateman; Lisa Easom Howard
Journal:  Front Pediatr       Date:  2016-03-21       Impact factor: 3.418

7.  Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection.

Authors:  Baek Gyu Jun; Woong Cheul Lee; Jae Young Jang; Soung Won Jeong; Young Chang; Sae Hwan Lee; Young Don Kim; Sang Gyune Kim; Gab Jin Cheon; Young Seok Kim; Hong Soo Kim; So Young Jin
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.